ID   YaFuSS
AC   CVCL_L809
DR   Cosmic; 1319810
DR   GEO; GSM2887620
DR   GEO; GSM2887621
DR   Wikidata; Q54995201
RX   PubMed=15814652;
RX   PubMed=27353471;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; HGNC:11340; SS18 + HGNC; HGNC:11335; SSX1; Name(s)=SS18-SSX1 (PubMed=15814652).
CC   Omics: Transcriptomics; RNAseq.
DI   NCIt; C6534; Monophasic synovial sarcoma
DI   ORDO; Orphanet_3273; Synovial sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-04-25; Version: 16
//
RX   PubMed=15814652; DOI=10.1158/1078-0432.CCR-04-2057;
RA   Ishibe T., Nakayama T., Okamoto T., Aoyama T., Nishijo K.,
RA   Shibata K.R., Shima Y., Nagayama S., Katagiri T., Nakamura Y.,
RA   Nakamura T., Toguchida J.;
RT   "Disruption of fibroblast growth factor signal pathway inhibits the
RT   growth of synovial sarcomas: potential application of signal
RT   inhibitors to molecular target therapy.";
RL   Clin. Cancer Res. 11:2702-2712(2005).
//
RX   PubMed=27353471; DOI=10.1111/gtc.12387;
RA   Yamasaki H., Miyamoto M., Yamamoto Y., Kondo T., Watanabe T., Ohta T.;
RT   "Synovial sarcoma cell lines showed reduced DNA repair activity and
RT   sensitivity to a PARP inhibitor.";
RL   Genes Cells 21:852-860(2016).
//